Compare MGNX & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNX | CURV |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.8M | 102.2M |
| IPO Year | 2013 | 2021 |
| Metric | MGNX | CURV |
|---|---|---|
| Price | $1.88 | $1.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $3.20 | $1.59 |
| AVG Volume (30 Days) | ★ 533.9K | 179.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.36 |
| EPS | N/A | ★ 0.01 |
| Revenue | $149,962,000.00 | ★ $1,103,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $101.00 |
| Revenue Growth | ★ 155.26 | N/A |
| 52 Week Low | $0.99 | $0.94 |
| 52 Week High | $2.49 | $6.95 |
| Indicator | MGNX | CURV |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 49.54 |
| Support Level | $1.62 | $0.96 |
| Resistance Level | $1.97 | $1.13 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 67.47 | 70.00 |
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.